Understanding Comorbidities of Respiratory Models as Novel Platforms for Drug Discovery.

Autor:	De Luca SN; Respiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia., Gunatilaka A; Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria 3010, Australia.; ARC Centre for Personalised Therapeutics Technologies, The University of Melbourne, Parkville, Victoria 3010, Australia., Coward-Smith M; Respiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia.; School of Life Sciences, University of Technology Sydney, Sydney, New South Wales 2007, Australia., Gomez HM; School of Biomedical Sciences and Pharmacy, University of Newcastle and Immune Health Program, Hunter Medical Research Institute, Newcastle, New South Wales 2308, Australia., Kim RY; School of Life Sciences, University of Technology Sydney, Sydney, New South Wales 2007, Australia.; School of Biomedical Sciences and Pharmacy, University of Newcastle and Immune Health Program, Hunter Medical Research Institute, Newcastle, New South Wales 2308, Australia.; Woolcock Institute of Medical Research, Macquarie Park, New South Wales 2113, Australia., Stenekes A; School of Life Sciences, University of Technology Sydney, Sydney, New South Wales 2007, Australia., Chan SMH; Respiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia., Wang W; Respiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia., Tan D; Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria 3010, Australia.; ARC Centre for Personalised Therapeutics Technologies, The University of Melbourne, Parkville, Victoria 3010, Australia., Vlahos R; Respiratory Research Group, Centre for Respiratory Science and Health, School of Health and Biomedical Sciences, RMIT University, Bundoora, Melbourne, Victoria 3083, Australia., Stewart AG; Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria 3010, Australia.; ARC Centre for Personalised Therapeutics Technologies, The University of Melbourne, Parkville, Victoria 3010, Australia., Donovan C; School of Life Sciences, University of Technology Sydney, Sydney, New South Wales 2007, Australia.; School of Biomedical Sciences and Pharmacy, University of Newcastle and Immune Health Program, Hunter Medical Research Institute, Newcastle, New South Wales 2308, Australia.; Woolcock Institute of Medical Research, Macquarie Park, New South Wales 2113, Australia.
Jazyk:	angličtina
Zdroj:	ACS pharmacology & translational science [ACS Pharmacol Transl Sci] 2024 Oct 25; Vol. 7 (11), pp. 3385-3393. Date of Electronic Publication: 2024 Oct 25 (Print Publication: 2024).
DOI:	10.1021/acsptsci.4c00484
Abstrakt:	Chronic respiratory diseases affect over 450 million people worldwide and result in 4 million deaths per year. The majority of lung diseases are treated with drugs delivered directly to the lungs. However, there is bidirectional crosstalk between the lung and other organs/tissues in health and disease. This crosstalk supports targeting of extrapulmonary sites in addition to the lung to improve the comorbidities associated with lung disease. However, new preclinical in vivo and in vitro assays that model the human pathophysiology are required. In this review, we showcase the latest knowledge of the bidirectional relationship between the respiratory system and organs affected by comorbidities such as obesity and atherosclerosis. We also discuss the impact of new cell culture systems, including complex 3D culture models that may be used as platforms to generate disease insights and for drug discovery. This review highlights work presented by Respiratory and Inflammation Special Interest Group researchers as part of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) annual scientific meeting in 2023. Competing Interests: The authors declare no competing financial interest. (© 2024 American Chemical Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu